ASPECT BIOSYSTEMS TO PRESENT PRECLINICAL MENISCUS DATA AT ORTHOPAEDIC RESEARCH SOCIETY 2019 MEETING
3D Bioprinted Meniscus Tissue From Biocompatible Materials Displays Appropriate Biomechanical Properties for Surgical Implantation and Physiological Function
VANCOUVER, British Columbia – January 29, 2019 – Aspect Biosystems Ltd., a Canadian biotech company pioneering microfluidic 3D bioprinting of human tissues, today announced it will present preclinical data from recent studies focused on developing a bioprinted meniscus tissue with mechanical properties suitable for surgical implantation. The Company’s data has been selected for an oral (Poster Pitch) and poster presentation at the Orthopaedic Research Society (ORS) 2019 Annual Meeting in Austin, Texas, Feb. 2-5, 2019, and will highlight biomechanical accomplishments from this therapeutic tissue program.
“We’re pleased to present data demonstrating that our microfluidic 3D bioprinting technology is capable of fabricating high-strength implantable tissues for orthopaedic applications. Through this study, we are encouraged to see that our 3D bioprinted meniscus tissues demonstrate key biomechanical properties that are necessary for surgical implantation,” said Sam Wadsworth, PhD, chief scientific officer, Aspect Biosystems. “This is the first time we will present data at the ORS, the world’s leading conference of its kind. It’s an honour to be selected as a finalist for a Meniscus Section Poster Award.”
Meniscus injuries are one of the most common injuries of the knee joint. The meniscus demonstrates poor healing potential and there is significant clinical need for effective and long-term meniscal replacement therapies. Through the course of this study, Aspect’s unique microfluidic 3D bioprinting technology was used to pattern biocompatible, FDA-approved materials in a manner that recreates many of the structural and mechanical properties of native meniscus tissue. Aspect intends for this work to lead to subsequent efforts to assess the biomechanical function of bioprinted menisci in in vivostudies.
“We are delighted to see promising early data from this therapeutic tissue program, and are eager to see this work advance to the next stages of development,” said Tamer Mohamed, president and chief executive officer, Aspect Biosystems. “Currently, there aren’t many options for patients with degenerative meniscus injuries. We are excited to see the strong potential of our microfluidic bioprinting technology addressing an area of unmet medical need and look forward to continue expanding our efforts in developing next-generation tissue therapeutics for regenerative medicine.”
The Company’s presentations are as follows:
Publication #0521 – A Meniscus Tissue Bioprinted From Biocompatible Materials Displays Appropriate Biomechanical Properties for Surgical Implantation and Physiological Function
Poster Pitch (Oral)
Date: Saturday, Feb. 2, 1:40 PM
Location: Meniscus Session
Presenter: Sam Wadsworth, PhD, chief scientific officer, Aspect Biosystems
Date: Sunday, Feb. 3, 9:00 AM-10:00 AM
Location: Session PS1-010: Meniscus – Treatment and Therapeutics
Presenter: Sam Wadsworth, PhD, chief scientific officer, Aspect Biosystem
ABOUT THE ORTHOPAEDIC RESEARCH SOCIETY (ORS)
For over 60 years, the Orthopaedic Research Society has been the leading research society supporting engineers, orthopaedic surgeons, veterinarians, biologists, and clinicians in pursuit of a world without musculoskeletal limitations. The ORS continues to bring together the best researchers and surgeons in the world and gives them a community to share new research findings, discuss new ideas and to collaborate in new and innovative ways. The ORS Annual Meeting is the leading forum for the presentation of high-quality, innovative and transformative research.
ABOUT ASPECT BIOSYSTEMS
Aspect Biosystems Ltd. is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery,and regenerative medicine products.